# Sprifermin (AS902330) in Cartilage Injury Repair (CIR)

> **NCT01066871** · PHASE2 · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 74 (actual)

## Conditions studied

- Isolated Cartilage Injury of the Knee

## Interventions

- **DRUG:** Sprifermin (AS902330) 10 mcg
- **DRUG:** Sprifermin (AS902330) 30 mcg
- **DRUG:** Sprifermin (AS902330) 100 mcg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01066871
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 74 (ACTUAL)
- **Why stopped:** The study was discontinued due to low recruitment.
- **Last updated:** 2016-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01066871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01066871, "Sprifermin (AS902330) in Cartilage Injury Repair (CIR)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01066871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*